Cyclo Therapeutics, Inc.: Nasdaq/NYSE listing notice — Cyclo Therapeutics receives Nasdaq delisting notice for negative equity

Cyclo Therapeutics, Inc.

Stockholders' equity of -$438,876 as of Mar 31, 2023, below Nasdaq's $2.5M minimum.
Company has until June 29, 2023 to submit a compliance plan to Nasdaq.
If plan is accepted, Nasdaq may grant an extension of up to 180 days to regain compliance.
Failure could lead to suspension or delisting, with right to a hearing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 15, 2023, Cyclo Therapeutics, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $(438,876) as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000. Pursuant to Nasdaq’s Listing Rules, the Company has 45 calendar days (until June 29, 2023), to submit a plan to regain compliance with the Rule (a “Compliance Pla

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-015116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.